Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
2.960
+0.153 (5.44%)
Jun 27, 2025, 4:00 PM - Market closed

Cyclerion Therapeutics Statistics

Total Valuation

CYCN has a market cap or net worth of $9.50 million. The enterprise value is $5.37 million.

Market Cap 9.50M
Enterprise Value 5.37M

Important Dates

The next estimated earnings date is Wednesday, August 6, 2025, before market open.

Earnings Date Aug 6, 2025
Ex-Dividend Date n/a

Share Statistics

CYCN has 3.21 million shares outstanding. The number of shares has increased by 4.80% in one year.

Current Share Class 3.21M
Shares Outstanding 3.21M
Shares Change (YoY) +4.80%
Shares Change (QoQ) +0.55%
Owned by Insiders (%) 22.92%
Owned by Institutions (%) 16.31%
Float 2.31M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 3.42
Forward PS n/a
PB Ratio 0.98
P/TBV Ratio 1.03
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 2.58
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.21

Current Ratio 4.21
Quick Ratio 3.96
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -31.48% and return on invested capital (ROIC) is -23.17%.

Return on Equity (ROE) -31.48%
Return on Assets (ROA) -20.43%
Return on Invested Capital (ROIC) -23.17%
Return on Capital Employed (ROCE) -39.49%
Revenue Per Employee $2.08M
Profits Per Employee -$2.94M
Employee Count 1
Asset Turnover 0.20
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +18.15% in the last 52 weeks. The beta is 1.55, so CYCN's price volatility has been higher than the market average.

Beta (5Y) 1.55
52-Week Price Change +18.15%
50-Day Moving Average 3.08
200-Day Moving Average 2.91
Relative Strength Index (RSI) 46.47
Average Volume (20 Days) 19,149

Short Selling Information

The latest short interest is 32,317, so 1.01% of the outstanding shares have been sold short.

Short Interest 32,317
Short Previous Month 25,697
Short % of Shares Out 1.01%
Short % of Float 1.40%
Short Ratio (days to cover) 1.82

Income Statement

In the last 12 months, CYCN had revenue of $2.08 million and -$2.94 million in losses. Loss per share was -$1.16.

Revenue 2.08M
Gross Profit 2.08M
Operating Income -3.47M
Pretax Income 3.01M
Net Income -2.94M
EBITDA n/a
EBIT -3.47M
Loss Per Share -$1.16
Full Income Statement

Balance Sheet

The company has $3.64 million in cash and n/a in debt, giving a net cash position of $3.64 million or $1.13 per share.

Cash & Cash Equivalents 3.64M
Total Debt n/a
Net Cash 3.64M
Net Cash Per Share $1.13
Equity (Book Value) 8.78M
Book Value Per Share 2.87
Working Capital 3.43M
Full Balance Sheet

Cash Flow

Operating Cash Flow -3.43M
Capital Expenditures n/a
Free Cash Flow -3.43M
FCF Per Share -$1.07
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -166.60% and -141.47%.

Gross Margin 100.00%
Operating Margin -166.60%
Pretax Margin -141.47%
Profit Margin -141.47%
EBITDA Margin n/a
EBIT Margin -166.60%
FCF Margin n/a

Dividends & Yields

CYCN does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -4.80%
Shareholder Yield -4.80%
Earnings Yield -32.67%
FCF Yield -38.06%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on May 16, 2023. It was a reverse split with a ratio of 0.05:1.

Last Split Date May 16, 2023
Split Type Reverse
Split Ratio 0.05:1

Scores

CYCN has an Altman Z-Score of -34.68 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -34.68
Piotroski F-Score 1